AI robot teaches patients about clinical trials – will it boost participation?
NCT ID NCT07305337
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an AI-powered chatbot can help people with blood cancers like leukemia and lymphoma better understand clinical trials and feel more willing to join them. Researchers will compare patients who get standard education plus AI chatbot sessions to those who only get standard education. The goal is to see if AI can improve trial literacy and decision-making.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Artificial Intelligence Health Education (AI chatbot)
- What this could lead to
- If successful, this could show that AI chatbots are a useful tool to help patients learn about clinical trials and make informed decisions.
- What could go wrong
- This is a small, early-stage study focused on education, not treatment. It may not prove that AI education actually increases trial enrollment or works in other settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongnan Hospital of Wuhan University
RECRUITINGWuhan, Hubei, 430071, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Frailty check may steer safer cancer care for seniors
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?